

Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Comparative Biochemistry and Physiology, Part C

journal homepage: www.elsevier.com/locate/cbpcIsolation and functional characterization of proinflammatory acidic phospholipase A₂ from *Bothrops leucurus* snake venom

Déborá C.O. Nunes^a, Renata S. Rodrigues^b, Malson N. Lucena^c, Camila T. Cologna^b, Ana Carolina S. Oliveira^d, Amélia Hamaguchi^a, Maria I. Homsí-Brandeburgo^a, Eliane C. Arantes^b, David N.S. Teixeira^d, Carlos Ueira-Vieira^a, Veridiana M. Rodrigues^{a,e,*}

^a Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia, UFU, Uberlândia, MG, Brazil

^b Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, USP, Ribeirão Preto, SP, Brazil

^c Faculdade de Medicina, Universidade de São Paulo, USP, Ribeirão Preto, SP, Brazil

^d Departamento de Clínica Médica, Universidade Federal do Triângulo Mineiro, UFTM, Uberaba, MG, Brazil

^e Instituto Nacional de Ciência e Tecnologia em Nano-Biofarmacêutica (N-Biofar), 31270-901, Belo Horizonte, MG, Brazil

ARTICLE INFO

Article history:

Received 22 January 2011

Received in revised form 6 June 2011

Accepted 8 June 2011

Available online 15 June 2011

Keywords:

Acidic phospholipase A₂*Bothrops leucurus*

Cytokines

Proinflammatory profile

Snake venom

ABSTRACT

In the present study, an acidic PLA₂, designated BI-PLA₂, was isolated from *Bothrops leucurus* snake venom through two chromatographic steps: ion-exchange on CM-Sepharose and hydrophobic chromatography on Phenyl-Sepharose. BI-PLA₂ was homogeneous on SDS-PAGE and when submitted to 2D electrophoresis the molecular mass was 15,000 Da and pI was 5.4. Its N-terminal sequence revealed a high homology with other Asp49 acidic PLA₂s from snake venoms. Its specific activity was 159.9 U/mg and the indirect hemolytic activity was also higher than that of the crude venom. BI-PLA₂ induced low myotoxic and edema activities as compared to those of the crude venom. Moreover, the enzyme was able to induce increments in IL-12p40, TNF-α, IL-1β and IL-6 levels and no variation of IL-8 and IL-10 in human PBMC stimulated *in vitro*, suggesting that BI-PLA₂ induces proinflammatory cytokine production by human mononuclear cells. *Bothrops leucurus* venom is still not extensively explored and knowledge of its components will contribute for a better understanding of its action mechanism.

© 2011 Elsevier Inc. Open access under the [Elsevier OA license](http://creativecommons.org/licenses/by/3.0/).

1. Introduction

Phospholipase A₂–PLA₂ (EC 3.1.1.4)—is a class of enzymes that catalyze the hydrolysis of *sn*-2-acyl bond of *sn*-3-phospholipids, generating free fatty acids and lysophospholipids as products (van Deenen and de Haas, 1963) and are currently classified in 15 groups on the basis of disulphide bridge patterns, amino acid sequence similarity and catalytic mechanisms (Schaloske and Dennis, 2006). Snake venom PLA₂s are known to belong to groups I (Elapidae/Hydrophidae) and II (Viperidae/Crotalidae). The group II can be subdivided, subsequently, in two main subgroups, depending on the residue at position 49 in the primary structure: Asp49 (D49) are enzymatically active while Lys49 (K49) present low or no enzymatic activity (Lomonte et al., 2003). There are other subgroups, such as Asn49 (Tsai et al., 2004; Wei et al., 2006a), Ser49 (Krizaj et al., 1991; Polgar et al., 1996); Gln49 (Bao et al., 2005) and Arg49 (Chijiwa et al., 2006; Mebs et al., 2006; Wei et al., 2006b), but

Abbreviations: BI-PLA₂, acidic phospholipase A₂ from *Bothrops leucurus* venom; CK, creatine kinase; CV, crude venom; PBMC, peripheral blood mononuclear cell; PLA₂, phospholipase A₂; TFA, trifluoroacetic acid.

* Corresponding author at: Avenue Pará 1720 CEP: 38400–902, Uberlândia, MG, Brazil. Tel.: +55 34 32182203; fax: +55 34 3218 2203#22.

E-mail address: veridiana@ingeb.ufu.br (V.M. Rodrigues).

studies have found that catalytic activity is reduced or even abolished when an aspartic acid of native phospholipases A₂ is replaced by another amino acid (Li et al., 1994; Bao et al., 2005).

Snake venoms are rich sources of PLA₂s and these enzymes perform a variety of pharmacological and/or toxic effects, such as myotoxicity, hemolysis, edema, anticoagulation, effects on platelet aggregation, neurotoxicity, cardiotoxicity, hypotension, antitumoral and antimicrobial activities (Gutiérrez and Lomonte, 1997; Ketelhut et al., 2003; Stábeli et al., 2006; Rodrigues et al., 2007; Sami et al., 2008). Moreover, local inflammation is a prominent characteristic of snakebite envenomation by Viperidae and Crotalidae species (Dennis, 1994), due mainly to the presence of PLA₂s and metalloproteinases (Rucavado et al., 2002; Oliveira et al., 2009; Teixeira et al., 2009). The pathogenesis of systemic effects in *Bothrops* envenomation is complex, involving both the direct action of the venom components on the tissue and the release of various endogenous mediators (Petricevich et al., 2000). In literature, the action of both PLA₂s Asp49 and Lys 49 in skeletal muscle cells disruption, as well as its role in inflammatory reactions induction associated with edema, cellular infiltration and pain have been widely demonstrated (Barros et al., 1998; Petricevich et al., 2000; Carneiro et al., 2002; Chavez et al., 2005; Zamuner et al. 2005; Zuliani et al., 2005; Bonfim et al., 2008; Teixeira et al., 2009).

Bothrops leucurus (white-tailed-jararaca) was described by Wagler in 1824 (BSH, 2010) and occupy the Northeast and Southeast regions of Brazil, including Ceará, Bahia and Espírito Santo States (Porto and Teixeira, 1995). This species has a large medical importance. An epidemiological survey, conducted in Bahia State in 2001, reported that in cases of confirmed bothropic envenoming with the identification of the snake, all of them were attributed to *B. leucurus* (Mise et al., 2007). Some components were isolated from this venom such as three non-hemorrhagic metalloproteinases, leucurolysin-a (leuc-a) (Bello et al., 2006), leucurolysin-B (leuc-B) (Sanchez et al., 2007) and BleucMP (Gomes et al., 2011), a coagulant thrombin-like enzyme, named leucurobin (leuc) (Magalhães et al., 2007), two L-amino acid oxidase (Torres et al., 2010; Naumann, et al., 2011), two basic phospholipases A₂ designed *bID*-PLA₂ and *bIK*-PLA₂ (Higuchi et al., 2007) and a lectin (BIL) (Nunes et al., 2011).

The present article describes, for the first time, the isolation procedure and the biochemical characterization of a proinflammatory acidic phospholipase A₂ from *B. leucurus* venom, named *Bl*-PLA₂.

2. Materials and methods

2.1. Materials

B. leucurus snake venom was obtained from Bioagents Serpentarium (Batatais, SP, Brazil). CM-Sepharose, Phenyl-Sepharose CL-4B and C18 column were purchased from GE Healthcare. Ethylenediaminetetraacetic acid (EDTA), creatine kinase (CK-UV) kinetic kit, molecular weight protein standards and acrylamide were obtained from Sigma Chemical Co. The kits to cytokine measurement came from ELISA Set, BD OptEIA™–Human (BD Biosciences). All other chemical reagents were of analytical grade.

2.2. Animals and human blood

Swiss male mice were kindly provided by Vallée Institute (Minas Gerais, Brazil) and maintained under standard conditions (temperature 22 ± 1 °C, relative humidity 60 ± 5%, 12 h light/dark cycle) with diet and water *ad libitum*. The experimentation protocol was approved by the Committee of Ethics for the Use of Animals from Federal University of Uberlândia–Minas Gerais, Brazil (License number 08-2008) and is in agreement with ethical principles of animal experimentation adopted by the Brazilian Society of Science in laboratory animals. Human blood was collected from volunteers and approved by the Human Research Ethics Committees from Federal University of Triângulo Mineiro, Brazil (CEP-UFTM) (License number 1079).

2.3. Isolation of the acidic phospholipase A₂

Isolation of the acidic phospholipase A₂ was carried out according to Rodrigues et al. (2007), with some modifications. Samples of crude venom (86.3 mg) were dispersed into 2.0 mL of 0.05 M ammonium bicarbonate buffer, pH 7.8, cleared by centrifugation at 400×g for 10 min and applied on a CM-Sepharose *fast flow* column (2.0×20 cm) which was previously equilibrated and initially eluted with the same buffer. A gradient was then applied up to 0.5 M buffer and fractions of 3 mL/tube were collected at a flow rate of 20 mL/h. The fraction showing PLA₂ activity was lyophilized and then applied on a Phenyl-Sepharose CL-4B column (1.0×10 cm) equilibrated with 0.01 M Tris–HCl buffer plus 4 M NaCl, pH 8.5. Elution occurred at room temperature, by decreasing concentrations of NaCl (4, 3, 2, 1 and 0.5 M) still in 0.01 M Tris–HCl buffer, pH 8.5, ending the elution process with water.

The active fraction was applied on a reverse phase HPLC using a C18 column of 2.0×2.5 cm (Shimadzu), which was equilibrated with solvent A (0.1% trifluoroacetic acid and 5% acetonitrile) and eluted

under a concentration gradient of solvent B (60% acetonitrile, 0.1% trifluoroacetic acid) from 0 to 60% at a flow rate of 1 mL/min at room temperature. The protein contents were monitored at 280 nm and the single peak was separated and lyophilized to determine the N-terminal sequence and biochemical properties. Proteins were estimated by Bradford (1976).

2.4. Biochemical characterization

2.4.1. Electrophoresis

14% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli (1970). Samples were heated at 100 °C for 5 min and then ran under reducing (SDS + 10% β-mercaptoethanol) conditions. The molecular mass markers used were: Bovine serum albumin (66 kDa), ovalbumin (45 kDa), glyceraldehyde-3-phosphate dehydrogenase (36 kDa), carbonic anhydrase (29 kDa), trypsinogen (24 kDa), trypsin inhibitor (20.1 kDa), α-lactalbumin (14.4 kDa) (Amersham Biosciences).

2.4.2. Two-dimensional electrophoresis

In order to determine the molecular mass and pI, *Bl*-PLA₂ (25.0 μg) was precipitated with 2-D Clean-up kit (GE Healthcare), according to manufacturer's instructions. After drying, the precipitated was solubilized in 200 μL of re-hydration buffer (6 M urea; 2 M thiourea; 2% ASB-14 (p/v); 15 mM DTT; 0.002% bromophenol blue 1%) plus 0.5% (v/v) of IPG buffer, pH 3–10 (GE Healthcare). Re-hydration was performed on IPGPhor III (GE Healthcare) system and took place under voltage of 40 V for 14 h. We used polyacrylamide strips with immobilized pH gradient (Immobiline DryStrip) at pH 3–10 range and 11 cm in length (GE Healthcare). After re-hydration, strips were submitted to isoelectric focusing (IEF) on IPGPhor III, 34636 V/h.

After IEF, focused strips were incubated for 15 min in 10 mL of equilibrium solution (1.5 M Tris–HCl pH 8.8; 6 M urea; 30% v/v glycerol; 2% w/v SDS; 0.002% bromophenol blue 1% w/v) plus 10 mg/mL of DTT (USB), followed by a second incubation in the same buffer, with the inclusion of 25 mg/mL iodoacetamide (Sigma). Finally, strips were subjected to electrophoresis on SDS-PAGE 8–18% (GE Healthcare) in the Multiphor II system according to the program suggested by the manufacturer's manual. Gels were stained with colloidal coomassie blue (2% (w/v) coomassie G-250) for 72 h, destained in distilled water and kept in ethanol 70% (v/v) until your digitalization in the scanner Image Scanner (GE Healthcare), using the Image Master LabScan™ v 5.0 program (with 300 dpi resolution). Analyses were done visually and also by the Image Master 2D Platinum v 6.0 (GE Healthcare) program, as recommended in the manual. The reference gel was obtained as a result of biological triplicate analyses.

2.5. N-terminal sequence

Bl-PLA₂ (1 mg) was dissolved in 0.25 M Tris–HCl buffer, pH 8.2, containing 0.1% (w/v) EDTA. For each mole of Cys, 30 moles of dithiothreitol were added. After being flushed with N₂, the solution was incubated for 4 h at 50 °C in the dark. Excess vinylpyridine was then added and incubation proceeded overnight. The reduced sample was then purified on a C18 RP-HPLC column and its N-terminal sequence was determined using a model PPSQ-23A Perkin-Elmer Procise Sequenator (Applied Biosystem Division, Foster City, CA, USA) with on-line identification of the corresponding phenylthiohydantoin derivatives. The N-terminal amino acid sequence of *Bl*-PLA₂ was aligned with sequences available in the Gene Bank and Swiss-Prot databases using the Clustal program.

2.6. Enzymatic activity

PLA₂ activity was assayed as described by de Haas and Postema (1968). It was determined upon egg-yolk emulsion, which contains

phosphatidylcholine as substrate, using samples with 10 µg of proteins. For the indirect hemolysis method, washed mice erythrocytes and hen's egg-yolk emulsion were used as substrate (Gutiérrez et al., 1988). Each experiment was performed in triplicate and independent assays were done.

2.7. Myotoxic activity

Groups of three Swiss male mice (18–22 g) were injected intramuscularly (i.m.) in the gastrocnemius muscle with 20 µg of crude venom and 20 µg or 50 µg of *Bl*-PLA₂, dissolved in 50 µL of saline. The control group received only 50 µL of saline. After 3 h, the blood was collected by cardiac puncture in heparin-coated tubes and centrifuged at 320 × g for 10 min at 4 °C for plasma separation. Activity of creatine kinase (CK) (EC 2.7.3.2) was then determined using 10 µL plasma, which were incubated for 3 min at 37 °C with 1 mL of the reagent, according to the Laborlab Kinetic CK–UV protocol. Activity was expressed in U/L, one unit resulting from the phosphorylation of 1 µmol of creatine/min at 25 °C. Independent assays were done.

2.8. Edema-inducing activity

Groups of five Swiss male mice (18–22 g) were injected in the subplantar region with the crude venom or *Bl*-PLA₂ (20 µg/50 µL saline). After 0.25, 0.5, 1, 2, 3, 6 and 24 h, the paw edema was measured with the aid of a low-pressure spring caliper (Mitutoyo-Japan) (Rodrigues et al., 2001). Zero time values were then subtracted and the differences reported as mean ± S.D. Independent assays were done.

2.9. PBMC and cell culture

Peripheral blood mononuclear cells (PBMC) were obtained from human whole blood donated by healthy volunteers, after centrifugation on a Ficoll-Paque Plus density gradient (GE Healthcare). PBMC were cultivated in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 0.002 M L-glutamine, 0.002 M sodium pyruvate, 0.001 M non-essential amino acids, 100 UI/mL penicillin, 100 µg/mL streptomycin, and incubated at 37 °C with 5% CO₂, under standard procedures. The cells were cultured at density of 1 × 10⁶ cells/well in 24-well microplates. PBMC cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described by Mosmann (1983) after treatment with different doses of enzyme (2.5, 5 and 10 µg/well).

The PBMC were stimulated with crude venom or *Bl*-PLA₂ at different concentrations. Control PBMCs were cultured only in RPMI medium. The cells were incubated at 37 °C for 24 h. After stimulation, samples were centrifuged, the supernatants collected and stored at –70 °C before cytokine assays.

2.10. Cytokine measurement

TNF-α, IL-8, IL-12p40, IL-10, IL-1β and IL-6 levels in supernatants were measured by enzyme linked immunosorbent assay (ELISA), according to the manufacturer's instructions. Cytokine concentrations were then calculated by interpolation of the regression curve corresponding to known amounts of recombinant cytokines provided in the kit, and reported as pg/mL. Each experiment was done in triplicate and independent assays were done. Detection limits were: TNF-α, 1.4 pg/mL; IL-8, 0.6 pg/mL; IL-12p40, 1 pg/mL; IL-10, 1.2 pg/mL; IL-6, 4 pg/mL and IL-1β, 1.95 pg/mL.

2.11. Statistical analysis

The data were analyzed by Systat 10.2, BioStat5 and Statview softwares. The results were expressed as means ± standard deviation

(S.D.). Statistic significance of differences between groups was evaluated by ANOVA or Kruskal–Wallis tests and confirmed by Tukey and Tukey-type tests. A *p* value < 0.05 was considered to indicate statistically significant difference.

3. Results and discussion

Acidic PLA₂s have shown to be of high scientific interest due to their abundance in venom and their several functions acquired during evolution (Bonfim et al., 2008), such as bactericidal, antitumoral, parasitocidal and pro- or anti-inflammatory effects (Rucavado et al., 2002; Chacur et al., 2004; Rodrigues et al., 2004; Stábeli et al., 2006; Costa et al., 2008; Cruz et al., 2008; Nevalainen et al., 2008; Sami et al., 2008; Gebrim et al., 2009; Oliveira et al., 2009). Thus it becomes relevant to isolate and study the clinical potential of these enzymes.

Fractionations of *B. leucurus* venom by ion-exchange chromatography on CM-Sepharose column resulted in five major protein peaks (Fig. 1A). BL1 fraction, showing high phospholipase A₂ activity, was further fractionated on Phenyl Sepharose CL-4B and resolved into two new fractions, named BL1P1 and BL1P2 (Fig. 1B). BL1P2 was applied on a HPLC reverse-phase chromatographic column and presented one major peak, named *Bl*-PLA₂ (Fig. 1C).

The purification procedure according to Rodrigues et al. (2007) showed to be also efficient to isolate an acidic PLA₂ from *B. leucurus* snake venom, which corresponded to 5.4% of crude venom (Table 1), high percentage when compared to approximately 4% obtained for Bp-PLA₂, after Phenyl Sepharose (Rodrigues et al., 2007) and 1.8% for bID-PLA₂, after all purification procedure (Higuchi et al., 2007). Homogeneity of *Bl*-PLA₂ was further demonstrated by SDS-PAGE (Fig. 1D). The purified protein consisted of a single polypeptide chain with apparent approximate molecular weight of 15,000 and its *pI* was 5.4 (Fig. 1E).

The acidic PLA₂ (*Bl*-PLA₂) has an estimated molecular weight fitting with literature data which establish that snake venom PLA₂s present molecular weight varying between 13,000 and 18,000 (Ward et al., 2001). Higuchi et al. (2007) isolated two basic phospholipases A₂ from *B. leucurus* snake venom with molecular weight for both of 14,000.

The first sixty amino acids at the N-terminal sequence of *Bl*-PLA₂ were determined (Fig. 2). As this protein contained Asp at position 48 (position 49 of the catalytic dyad, according to numbering of Renetseder et al. (1985)), it was determined as an Asp49 PLA₂. The N-terminal sequence analysis of *Bl*-PLA₂ showed that it contains all of phospholipase A₂ conserved residues involved in the calcium binding and in the catalytic network (Tyr28, Gly30, Gly32, His48 and Asp49) (Renetseder et al., 1985; Kudo and Murakami, 2002). N-terminal sequences alignments of *Bl*-PLA₂ with those of other bothropic Asp49-PLA₂s showed a high identity with acidic D49-PLA₂s, highlighting those from *B. jararacussu* (100%), *B. pirajai* (86%) and *B. insularis* (81%). The lowest identity observed between *Bl*-PLA₂ and acidic D49-PLA₂s was for *B. moojeni* (63%). On the other hand, alignments between *Bl*-PLA₂ and basic Asp49-PLA₂s showed identities around 60%, one more strong evidence of acidic character of *Bl*-PLA₂ (Fig. 2).

The specific PLA₂ activity of *Bl*-PLA₂ was 159.9 ± 11.9 U/mg, approximately two-folds higher than that of the crude venom (69.3 U/mg) (Table 1). Indirect hemolytic activity presented by *Bl*-PLA₂ was also higher than that of the crude venom (Table 1).

Bl-PLA₂ induced low myotoxicity when compared with crude venom (Table 2), regardless of enzyme concentration. Low or no myotoxicity was also observed for four isoforms (SIIISPIIA, SIIISPIIB, SIIISPIIIA and SIIISPIIIB) of acidic PLA₂s isolated from *B. jararacussu* (Ketelhut et al., 2003), BE-I-PLA₂, an acidic D49 phospholipase A₂ from *B. erythromelas* (Modesto et al., 2006), BaspPLA₂-II, a basic D49-PLA₂ from *B. asper* (Fernández et al., 2010) and for an acidic PLA₂, Ba SpII RP4, isolated from *B. alternatus* (Denegri et al., 2010). In general, acidic AspPLA₂s are less myotoxic than basic PLA₂s, although they are




Fig. 1. Sequential purification steps of *BI-PLA₂*. (A) *Bothrops leucurus* venom (86.3 mg) on CM-Sepharose *fast flow*, in 0.05 M ammonium bicarbonate buffer, pH 7.8. A gradient was then applied up to 0.5 M buffer and fractions of 3 mL/tube were collected at a flow rate of 20 mL/h. (B) Rechromatography of the active fraction, named BL1 (55 mg), on a column of Phenyl-Sepharose CL-4B previously equilibrated with 10 mM Tris-HCl buffer, pH 8.5 plus 4 M NaCl at room temperature and then eluted with a decreasing concentration gradient from 4 to 0 M NaCl plus 0.01 M Tris-HCl buffer, pH 8.5, finishing with water. (C) *PLA₂* isolation (*BI-PLA₂*) on a Shimadzu C18 reverse-phase high-performance liquid chromatography (RP-HPLC) column. (D) SDS-PAGE (14%) of the purified *PLA₂*. Lines: (PM) molecular weight marker, (1) reduced *BI-PLA₂* (10 µg), (2) non-reduced *BI-PLA₂* (10 µg). (E) Bidimensional electrophoresis: *pI* ~5.4 for *BI-PLA₂* was determined using the method previously described (see Methods section).

enzymatically more active (Ketelhut et al., 2003). Several studies have pointed out to a myotoxic site in Lys49-*PLA₂* enzymes (residues 115–116 to 129) constituted by combination of positively charged and hydrophobic residues in C-terminal region, while non-myotoxic D49 *PLA₂*s present, predominantly, neutral and negatively charged surfaces, which do not permit the approach to negatively charged membranes (Núñez et al., 2001; Chioato and Ward, 2003; Murakami and Arni, 2003). Dos Santos et al. (2009) suggest that following

residues Lys20, Lys115, Arg118 and Tyr119, conserved in all bothropic Lys49-*PLA₂*s, are important to myotoxic action and they would be absent in Asp49-*PLA₂*s. Moreover, dimer formation in myotoxic *PLA₂*s results in increase in the area of the positively charged surface, which probably plays an important role in the recognition of the muscle membranes and, consequently, in the expression of myotoxic activity (Murakami and Arni, 2003). Finally, the lack of myotoxic activity may be explained by the access to the active site of the enzyme is through a

Table 1

Percent recoveries (% Rec.), phospholipase *A₂* and hemolytic activities along the purification procedure of acidic *PLA₂* from *B. leucurus* crude venom (*BI-PLA₂*).

Sample	Protein ^a		Phospholipase <i>A₂</i> Activity (U/mg) ^b	Hemolytic activity (mm) ^c				
	mg	% Rec		1 h	3 h	6 h	12 h	24 h
CV	86.3	100	69.3 ± 1.7	0	6.03 ± 0.57	10.31 ± 0.59	14.77 ± 0.42	22.06 ± 0.73
Step 1: CM-Sepharose (fraction BL1)	55	63.7	141.2 ± 11.5 ^d	0	9.53 ± 0.5 ^{d,e}	14.27 ± 0.05 ^{d,e}	19.12 ± 0.71 ^{d,e}	28.68 ± 1.24 ^{d,e}
Step 2: Phenyl Sepharose (fraction BL1P2)	4.7	5.4	158.7 ± 11.9 ^d	0	9.96 ± 0.4 ^d	14.94 ± 1.71 ^d	20.77 ± 0.63 ^d	34.52 ± 0.93 ^d
Purity assay: RP-HPLC (<i>BI-PLA₂</i>)	1.0 ^f	–	159.9 ± 11.9 ^d	0	10.95 ± 0.6 ^{d,e}	16.35 ± 1.64 ^{d,e}	21.03 ± 1.19 ^{d,e}	35.47 ± 1.05 ^{d,e}

^a Bradford method (Bradford, 1976).

^b *PLA₂* activity (de Haas and Postema, 1968).

^c Indirect hemolytic activity (Gutiérrez et al., 1988) expressed in mm at different time intervals (*n* = 3).

^d Statistically significant difference (*p* < 0.05) in relation to CV. (^e) Statistically significant difference between BL1 and *BI-PLA₂* (*p* < 0.05).

^e Statistically significant difference between BL1 and *BI-PLA₂* (*p* < 0.05).

^f 1.0 mg of BL1P2 was applied on Shimadzu C18 column, just to evaluate the purity assay.



Fig. 2. Comparison of the N-terminal amino acid sequence of *B. leucurus* PLA₂ (*Bl*-PLA₂) with other bothropic Asp49-PLA₂s. (A) Acidic D49-PLA₂s: *BthA*-I-PLA₂ from *B. jararacussu* (GI: 56554156), *Bpir* PLA₂-I from *B. pirajai* (GI: 258676481), *BinTX*-I from *B. insularis* (GI: 26006832), *Basp*PLA₂-II from *B. asper* (GI: 292630844), *BE*-I-PLA₂ from *B. erythromelas* (GI: 86450426), *Bpictus*-PLA₂ from *B. pictus* (GI: 9652397), *Ba* SPII RP4 from *B. alternatus* (GI: 292630845), *Bp*-PLA₂ from *B. pauloensis* (Rodrigues et al., 2007), *BmooTX*-I from *B. moojeni* (Santos-Filho et al., 2008). (B) Basic D49-PLA₂s: *BthTX*-II from *B. jararacussu* (Pereira et al., 1998), *BmTX*-I from *B. moojeni* (GI:221272396), *BnpTX*-I e *BnpTX*-II from *B. neuwiedi* (Rodrigues et al., 2004). Conserved residues involved in calcium binding (Tyr28, Gly30 and Gly32) and in catalytic network (His48 and Asp49) are marked.

narrow channel in the non-myotoxic Asp49 PLA₂, meanwhile this channel is much wider in myotoxic Lys49PLA₂s (Murakami and Arni, 2003; Denegri et al., 2010).

Bl-PLA₂ was able to induce maximum edema in 30 min, compared with 1 h for the crude venom (Table 2). Several studies have demonstrated that the edema onset and the time required to achieve maximum levels vary considerably (Selistre et al., 1990), depending on changes in composition and origin of venoms, as well as differences in species of animals used as experimental model. The mechanism by which catalytically active PLA₂s induce edema may be explained by phospholipid hydrolysis, probably due to liberation of precursors of eicosanoids and platelet activator factors. Liberation of amines by mast cells was proposed as a possible mechanism of edema induction by PLA₂s (Landucci et al., 2000). It is also important to note that the catalytic activity has an important role, but it is not decisive in edematogenic effect, that is, the phospholipases A₂ may have a phar-

macological domain independent of the catalytic site (Kini and Evans, 1989; Bonfim et al., 2008), since some Lys49 PLA₂s are able to induce edema (Soares et al., 2000; Oliveira et al., 2009).

Cell viability analysis was carried out to verify whether *Bl*-PLA₂ induces cytotoxic effects in the human PBMC. The cells were treated with different doses (2.5, 5 and 10 µg *Bl*-PLA₂/well) which were shown to be non-cytotoxic (Fig. 3). PBMC cells were used, whereas in previous studies it was found that PLA₂s could recruit leukocytes infiltration, mainly mononuclear cells, and that PLA₂s could induce such cells to release cytokines (Wei et al., 2006b). In this work, for the first time, we showed *in vitro*, the releasing profile of some pro and antiinflammatory cytokines by an acidic PLA₂ from *B. leucurus*. As result, we found that human PBMC stimulated *in vitro* with *Bl*-PLA₂ showed increments in IL-12p40, TNF-α, IL-1β and IL-6 levels in a dose-dependent manner, while no variation for IL-8 and IL-10 were observed (Fig. 4).

Table 2

Myotoxic and edematogenic activities of crude venom from *B. leucurus* and *Bl*-PLA₂.

Sample	CK (U/mL) ^a	Edema (%) ^b						
		0.25 h	0.5 h	1 h	2 h	3 h	6 h	24 h
Control	8.65 ± 0.97	5.79 ± 1.71	6.02 ± 2.79	6.66 ± 2.66	1.78 ± 0.9	1.1 ± 0.64	0.2 ± 0.1	0.2 ± 0.1
CV	55.65 ± 5.07	16.84 ± 4.65	23.16 ± 4.2	24.76 ± 2.96	20.96 ± 4.15	17.6 ± 5.26	15.34 ± 6.25	11.18 ± 4.22
<i>Bl</i> -PLA ₂ (20 µg)	10.51 ± 1.79 ^c	9.16 ± 2.26	11.92 ± 3.28	4.06 ± 1.22	2.85 ± 0.81	1.3 ± 0.36	0.96 ± 0.28	0.75 ± 0.24
<i>Bl</i> -PLA ₂ (50 µg)	14.16 ± 2.69 ^c	–	–	–	–	–	–	–

^a 20 µg of CV and 20 or 50 µg of *Bl*-PLA₂ were injected in the right gastrocnemius muscle of Swiss male mice (*n* = 5). After 3 h, the animals were sacrificed and their blood was collected by cardiac puncture for later analysis of creatine kinase.

^b 20 µg of CV or *Bl*-PLA₂ were injected in the subplantar region of Swiss male mice (*n* = 5). The increase of edema was measured after different intervals of time (Rodrigues et al., 2001).

^c Statistically significant difference (*p* < 0.05) in relation to control and crude venom (CV).




Fig. 3. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] metabolism by 2.0×10^5 peripheral blood mononuclear cells (PBMC) cultured in presence of different concentrations of BI-PLA₂ (2.5, 5.0 and 10.0 µg/mL) during 4 h at 37 °C/5% CO₂.

Inflammation is a major characteristic of envenomation by snakes from Viperinae and Crotalinae species (Rosenfeld, 1971; Sawai, 1980). Raised levels of proinflammatory cytokines have been detected in the serum of human victims or in experimental models following *Bothrops* and *Crotalus* envenoming (Barraviera et al., 1995; Barros et al., 1998; Petricevich et al., 2000; Cardoso et al., 2001; Carneiro

et al., 2002; Rucavado et al., 2002; Chavez et al., 2005; Cruz et al., 2005; Zamuner et al., 2005; Zuliani et al., 2005; Cruz et al., 2008).

In their study, Wei et al. (2006b) showed that Promutoxin (Arg49), a PLA₂ isolated from *Protobothrops mucrosquamatus*, was also able to evoke TNF, IL-6 and IL-1β releasing in a dose-dependent manner and increased level of IL-12 in a concentration independent manner. We also observed that BnSP-7, a basic Lys49 myotoxin isolated from *Bothrops (neuwiedi) pauloensis*, was able to induce increments in proinflammatory cytokines, such as IL-6 and IL-1β, by skeletal muscle cells (Oliveira et al., 2009). Another study testing two basic PLA₂s showed that both MT-II (catalytically inactive) and MT-III (catalytically active) induced increase in IL-1 and IL-6 levels in peritoneal fluid (Zuliani et al., 2005).

Mechanisms involved in the proinflammatory action of snake venoms are being actively investigated and most of this knowledge is based on studies using purified venom PLA₂s. This action can result by the different mechanisms such as enzymatic hydrolysis of phospholipids through the direct release of arachidonic acid from the plasma membrane; activation of intracellular processes in target cells (Zuliani et al., 2005) or interaction of distinct molecular regions in the catalytic site of Lys-49 PLA₂ with cell membranes which induce cell activation leading to an inflammatory reaction (Teixeira et al., 2003; Zuliani et al., 2005).




Fig. 4. Cytokines levels on PBMC culture. The production of IL-8 (A), IL-12p40 (B), TNF-α (C), IL-10 (D), IL-1β (E) and IL-6 (F) by PBMC were assayed in supernatants of cells stimulated with different concentrations (2.5, 5 and 10 µg/well) of BIPLA₂. The experiments were performed in triplicate and analyzed statistically by ANOVA or Kruskal–Wallis tests and confirmed by Tukey and Tukey-type tests. (a) Corresponds to $p < 0.05$ between the experimental groups and control group. (b) Corresponds to $p < 0.01$ between the experimental groups and control group.

Thus, *BI-PLA₂*, the newest acidic Asp 49 *PLA₂* from *B. leucurus*, becomes a good target for study due to its inflammatory potential and low cytotoxicity. A better understanding of *PLA₂* action mechanism in inflammatory process could provide important clues to comprehend the crude venom action and to develop novel therapeutic strategies to treat snakebite envenomation.

4. Conclusion

BI-PLA₂, the acidic *PLA₂* from *B. leucurus* snake venom, was isolated through two chromatographic steps, presenting an excellent purity degree. It possesses an Asp at the site 49, and therefore being classified as D49 *PLA₂*. *BI-PLA₂* did not show myotoxic activity, but induces edema and secretion of some proinflammatory cytokines from highly purified human monocytes, suggesting that it actively participates in the pathogenesis of snake bite.

Conflict of interest statement

No potential conflict of interest.

Acknowledgments

The authors express their gratitude to Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for financial support. We thank Prof. Dr. Luis Ricardo Goulart and Msc Paula de Souza Santos (UFU, Brazil) for technical support in two-dimensional electrophoresis analysis.

References

- Bao, Y., Bu, P., Jin, L., Wang, H., Yang, Q., An, L., 2005. Purification, characterization and gene cloning of a novel phospholipase *A₂* from the venom of *Agkistrodon lomhoffii ussuriensis*. *Int. J. Biochem. Cell Biol.* 37, 558–565.
- Barraviera, B., Lomonte, B., Tarkowski, A., Hanson, I.A., Maira, D.A., 1995. Acute-phase reactions, including cytokines, in patients bitten by *Bothrops* and *Crotalus* snakes in Brazil. *J. Venom. Anim. Toxins.* 1, 11–22.
- Barros, S.F., Friedlanskaia, I., Petricevich, V.L., Kipnis, T.L., 1998. Local inflammation, lethality and cytokine release in mice injected with *Bothrops atrox* venom. *Mediators Inflamm.* 7, 339–346.
- Bello, C.A., Hermogenes, A.L.N., Magalhães, A., Veiga, S.S., Gremski, L.H., Richardson, M., Sanchez, E.F., 2006. Isolation and biochemical characterization of a fibrinolytic proteinase from *Bothrops leucurus* (white-tailed-jararaca) snake venom. *Biochimie* 88, 189–200.
- Bonfim, V.L., de Carvalho, D.D., Ponce-Soto, L.A., Kassab, B.H., Marangoni, S., 2008. Toxicity of phospholipases *A₂* D49 (6–1 and 6–2) and K49 (Bj-VII) from *Bothrops jararacussu* venom. *Cell Biol. Toxicol.* 25, 523–532.
- Bradford, M.A., 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye-binding. *Anal. Biochem.* 72, 248–254.
- BSH, 2010. Lista de espécies de répteis do Brasil. Sociedade Brasileira de Herpetologia (SBH). Access in: <http://www.sberpetologia.org.br/>.
- Cardoso, D.F., Lopes-Ferreira, M., Faquim-Mauro, E., Macedo, M.S., Farsky, S.H.P., 2001. Role of crotoxin, a phospholipase *A₂* isolated from *Crotalus durissus terrificus* snake venom, on inflammatory and immune reactions. *Mediators Inflamm.* 10, 125–133.
- Carneiro, A.S., Ribeiro, O.G., Franco, M., Cabrera, W.H.K., Vorraro, F., Siqueira, M., Ibanez, O.M., Starobinas, N., 2002. Local inflammatory reaction induced by *Bothrops jararaca* venom differs in mice selected for acute inflammatory response. *Toxicol.* 40, 1571–1579.
- Chacur, M., Milligan, E.D., Sloan, E.M., Wieseler-Frank, J., Barrientos, R.M., Martin, D., Poole, S., Lomonte, B., Gutiérrez, J.M., Maier, S.F., Cury, Y., Watkins, L.R., 2004. Snake venom phospholipases *A₂* (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide. *Pain* 108, 180–191.
- Chavez, F., Teixeira, C.F.P., Gutiérrez, J.N., 2005. Role of TNF- α , IL-1 β and IL-6 in the local tissue damage induced by *Bothrops asper* snake venom: an experimental assessment in mice. *Toxicol.* 45, 71–78.
- Chijiwa, T., Tokunaga, E., Ikeda, R., Terada, K., Ogawa, T., Oda-Ueda, N., Hattori, S., Nozaki, M., Ohno, M., 2006. Discovery of novel [Arg49] phospholipase *A₂* isozymes from *Protobothrops elegans* venom and regional evolution of Crotalinae snake venom phospholipase *A₂* isozymes in the southwestern islands of Japan and Taiwan. *Toxicol.* 48, 672–682.
- Chioato, L., Ward, R.J., 2003. Mapping structural determinants of biological activities in snake venom phospholipases *A₂* by sequence analysis and site directed mutagenesis. *Toxicol.* 42, 869–883.
- Costa, T.R., Menaldo, D.L., Oliveira, C.Z., Santos-Filho, N.A., Teixeira, S.S., Nomizo, A., Fuly, A., Monteiro, M.C., Souza, B.M., Palma, M.S., Stábéli, R.G., Sampaio, S.V., Soares, A.M., 2008. Myotoxic phospholipases *A₂* isolated from *Bothrops brazili* snake venom and synthetic peptides derived from their C-terminal region: cytotoxic effect on microorganism and tumor cells. *Peptides* 29, 1645–1656.
- Cruz, A.H., Mendonça, R.Z., Petricevich, V.L., 2005. *Crotalus durissus terrificus* venom interferes with morphological, functional, and biochemical changes in murine macrophage. *Mediators Inflamm.* 6, 349–359.
- Cruz, A.H., Garcia-Jimenez, S., Mendonça, R.Z., Petricevich, V.L., 2008. Pro- and anti-inflammatory cytokines release in mice injected with *Crotalus durissus terrificus* venom. *Mediators Inflamm.* 2008, 1–10.
- de Haas, G.H., Postema, N.M., 1968. Purification and properties of phospholipase *A₂* from porcine pancreas. *Biochim. Biophys. Acta* 159, 103–117.
- Denegri, M.E.G., Costa, O.C.A., Huancahuire-Veja, S., Martins-de-Souza, D., Marangoni, S., Maruñak, S.L., Teibler, G.P., Leiva, L.C., Ponce-Soto, L.A., 2010. Isolation and functional characterization of a new acidic *PLA₂* Ba SpII RP4 of the *Bothrops alternatus* snake venom from Argentina. *Toxicol.* 56, 64–74.
- Dennis, E.A., 1994. Diversity of group types, regulation and function of phospholipases *A₂*. *J. Biol. Chem.* 269, 13057–13060.
- Dos Santos, J.I., Soares, A.M., Fontes, M.R.M., 2009. Comparative structural studies on Lys49-Phospholipase *A₂* from *Bothrops* genus reveal their myotoxic site. *J. Struct. Biol.* 167, 106–116.
- Fernández, J., Gutiérrez, J.M., Angulo, Y., Sanz, L., Juárez, P., Calvete, J.J., Lomonte, B., 2010. Isolation of an acidic phospholipase *A₂* from the venom of the snake *Bothrops asper* of Costa Rica: biochemical and toxicological characterization. *Biochimie* 92, 273–283.
- Gebrim, L.C., Marcussi, S., Menaldo, D.L., Menezes, C.S.R., Nomizo, A., Hamaguchi, A., Silveira-Lacerda, E.P., Homs-Brandeburgo, M.I., Sampaio, S.V., Soares, A.M., Rodrigues, V.M., 2009. Antitumor effects of snake venom chemically modified Lys49 phospholipase *A₂*-like BthTX-I and a synthetic peptide derived from its C-terminal region. *Biologicals* 37, 222–229.
- Gomes, M.S.R., Queiroz, M.R., Mamede, C.C.N., Mendes, M.M., Hamaguchi, A., Homs-Brandeburgo, M.I., Sousa, M.V., Aquino, E.N., Castro, M.S., Oliveira, F., Rodrigues, V.M., 2011. Purification and functional characterization of a new metalloproteinase (*BleucMP*) from *Bothrops leucurus* snake venom. *Comp. Biochem. Physiol. C* 153, 290–300.
- Gutiérrez, J.M., Lomonte, B., 1997. Phospholipase *A₂* myotoxins from *Bothrops* snake venoms. In: Kini, R.M. (Ed.), *Venom Phospholipase A₂ Enzymes: Structure, Function and Mechanism*. John Wiley & Sons, England, pp. 321–352.
- Gutiérrez, J.M., Ávila, C., Rojas, E., Cerdas, L., 1988. Alternative in vitro method for testing the potency of the polyvalent antivenom produced in Costa Rica. *Toxicol.* 26, 411–413.
- Higuchi, D.A., Barbosa, C.M.V., Bincioletto, C., Chagas, J.R., Magalhães, A., Richardson, M., Sanchez, E.F., Pesquero, J.B., Araujo, R.C., Pesquero, J.L., 2007. Purification and partial characterization of two phospholipases *A₂* from *Bothrops leucurus* (white-tailed-jararaca) snake venom. *Biochimie* 89, 319–328.
- Ketelhut, D.F., de Mello, M.H., Veronese, E.L., Esmeraldino, L.E., Murakami, M.T., Arni, R.K., Giglio, J.R., Cintra, A.C., Sampaio, S.V., 2003. Isolation, characterization and biological activity of acidic phospholipase *A₂* isoforms from *Bothrops jararacussu* snake venom. *Biochimie* 85, 983–991.
- Kini, R.M., Evans, H.J., 1989. A model to explain the pharmacological effects of snake venom phospholipases *A₂*. *Toxicol.* 27, 613–635.
- Krizaj, I., Bieber, A.L., Ritonja, A., Gubensek, F., 1991. The primary structure of ammodytin L, a myotoxic phospholipase *A₂* homologue from *Vipera ammodytes* venom. *Eur. J. Biochem.* 202, 1165–1168.
- Kudo, I., Murakami, M., 2002. Phospholipase *A₂* enzymes. *Prostaglandins Other Lipid Mediat.* 68–69, 3–58.
- Laemmli, U.K., 1970. Cleavage of structural proteins, during the assembly of the head of bacteriophage T4. *Nature* 227, 680–689.
- Landucci, E.C.T., Castro, R.C., Toyama, M., Giglio, J.R., de Nucci, G., Antunes, E., 2000. Inflammatory oedema induced by the Lys-49 phospholipase *A₂* homologue piratoxin-I in the rat and rabbit. Effect of polyanions and p-bromophenacyl. *Biochem. Pharmacol.* 59, 1289–1294.
- Li, Y., Yu, B.Z., Zhu, H., Jain, M.K., Tsai, M.D., 1994. Phospholipase *A₂* engineering. Structural and functional roles of the highly conserved active site residue aspartate-49. *Biochemistry* 33, 14714–14722.
- Lomonte, B., Angulo, Y., Calderón, L., 2003. An overview of lysine-49 phospholipase *A₂* myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. *Toxicol.* 42, 885–901.
- Magalhães, A., Magalhães, H.P.B., Richardson, M., Gontijo, S., Ferreira, R.N., Almeida, A.P., Sanchez, E.F., 2007. Purification and properties of a coagulant thrombin-like enzyme from the venom of *Bothrops leucurus*. *Comp. Biochem. Physiol. C* 146, 565–575.
- Mebs, D., Kuch, U., Coronas, F.I.V., Batista, C.V.F., Gumprecht, A., Possani, L.D., 2006. Biochemical and biological activities of the venom of the Chinese pitviper *Zhaovermia mangshanensis*, with the complete amino acid sequence and phylogenetic analysis of a novel Arg49 phospholipase *A₂* myotoxin. *Toxicol.* 47, 797–811.
- Mise, Y.F., Lira-da-Silva, R.M., Carvalho, F.M., 2007. Envenenamento por serpentes do gênero *Bothrops* no Estado da Bahia: aspectos epidemiológicos e clínicos. *Rev. Soc. Bras. Med. Trop.* 40, 569–573.
- Modesto, J.C.A., Spencer, P.J., Fritzen, M., Valença, R.C., Oliva, M.L.V., Silva, M.B., Chudzinski-Tavassi, A.M., Guarnieri, M.C., 2006. BE-I-*PLA₂*, a novel acidic phospholipase *A₂* from *Bothrops erythromelas* venom: isolation, cloning and characterization as potent anti-platelet and inducer of prostaglandin I₂ release by endothelial cells. *Biochem. Pharmacol.* 72, 377–384.

- Mosmann, T.J., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Immunomethods* 65, 55–63.
- Murakami, M.T., Arni, R.K., 2003. A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A₂s. *Toxicon* 42, 903–913.
- Naumann, G.B., Silva, L.F., Silva, L., Faria, G., Richardson, M., Evangelista, K., Kohlhoff, M., Gontijo, C.M.F., Navdaev, A., Rezende, F.F., Eble, J.A., Sanchez, E.F., 2011. Cytotoxicity and inhibition of platelet aggregation caused by an L-amino acid oxidase from *Bothrops leucurus* venom. *Biochim. Biophys. Acta* 1810 (7), 683–694.
- Nevalainen, T.J., Graham, G.G., Scott, K.F., 2008. Antibacterial actions of secreted phospholipases A₂. *Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids* 1781, 1–9.
- Nunes, E.S., Souza, M.A.A., Vaz, A.F.M., Santana, G.M.S., Gomes, F.S., Coelho, L.C.B.B., Paiva, P.M.G., Lira-da-Silva, R.M., Silva-Lucca, R.A., Oliva, M.L.V., Guarnieri, M.C., Correia, M.T.S., 2011. Purification of a lectin with antibacterial activity from *Bothrops leucurus* snake venom. *Comp. Biochem. Physiol. B*. doi:10.1016/j.cbpb.2011.02.001.
- Núñez, C.E., Angulo, Y., Lomonte, B., 2001. Identification of the myotoxic site of the Lys49 phospholipase A₂ from *Agkistrodon piscivorus piscivorus* snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. *Toxicon* 39, 1587–1594.
- Oliveira, C.F., Lopes, D.S., Mendes, M.M., Homsí-Brandeburgo, M.I., Hamaguchi, A., Alcântara, T.M., Clissa, P.B., Rodrigues, V.M., 2009. Insights of local tissue damage and regeneration induced by BnSP-7, a myotoxin isolated from *Bothrops (neuwiedi) pauloensis* snake venom. *Toxicon* 53, 560–569.
- Pereira, M.F., Novello, J.C., Cintra, A.C., Giglio, J.R., Landucci, E.T., Oliveira, B., Marangoni, S., 1998. The amino acid sequence of bothropstoxin-II, an Asp-49 myotoxin from *Bothrops jararacussu* (Jararacucu) venom with low phospholipase A₂ activity. *J. Protein Chem.* 17, 381–386.
- Petrichevich, V.L., Teixeira, C.F.P., Tambourgi, D.V., Gutiérrez, J.M., 2000. Increments in serum cytokine and nitric oxide levels in mice injected with *Bothrops asper* and *Bothrops jararaca* snake venoms. *Toxicon* 38, 1253–1266.
- Polgar, J., Magnenat, E.M., Peitsch, M.C., Wells, T.N., Clemetson, K.J., 1996. Asp-49 is not an absolute prerequisite for the enzymic activity of low-M(r) phospholipases A₂: purification, characterization and computer modelling of an enzymically active Ser-49 phospholipase A₂, ecarpholin S, from the venom of *Echis carinatus sochureki* (saw-scaled viper). *Biochem. J.* 319, 961–968.
- Porto, M., Teixeira, D.M., 1995. *Bothrops leucurus* (white-tailed lancehead). *Herpetol. Rev.* 26, 156.
- Renetseder, R., Brunie, S., Dijkstra, B.W., Drenth, J., Sigler, P.B., 1985. A comparison of the crystal structures of phospholipase A₂ from bovine pancreas and *Crotalus atrox* venom. *J. Biol. Chem.* 260, 11627–11634.
- Rodrigues, V.M., Soares, A.M., Andrião-Escarso, S.H., Franceschi, A.M., Rucavado, A., Gutiérrez, J.M., Giglio, J.R., 2001. Pathological alterations induced by neuwiedase, a metalloproteinase isolated from *Bothrops neuwiedi* snake venom. *Biochimie* 83, 471–479.
- Rodrigues, V.M., Marcussi, S., Cambraia, R.S., Araújo, A.L., Malta-Neto, N.R., Hamaguchi, A., Ferro, E.A.V., Homsí-Brandeburgo, M.I., Giglio, J.R., Soares, A.M., 2004. Bactericidal and neurotoxic activities of two myotoxic phospholipases A₂ from *Bothrops neuwiedi pauloensis* snake venom. *Toxicon* 44, 305–314.
- Rodrigues, R.S., Izidoro, L.F.M., Teixeira, S.S., Silveira, L.B., Hamaguchi, A., Homsí-Brandeburgo, M.I., Selistre-de-Araújo, H.S., Giglio, J.R., Fuly, A.L., Soares, A.M., Rodrigues, V.M., 2007. Isolation and functional characterization of a new myotoxic acidic phospholipase A₂ from *Bothrops pauloensis* snake venom. *Toxicon* 50, 153–165.
- Rosenfeld, G., 1971. Symptomatology, pathology and treatment of snake bites in South America. In: Bucherl, W., Buckley, E.E. (Eds.), *Venomous Animals and Their Venoms*. Academic Press, New York, pp. 345–403.
- Rucavado, A., Escalante, T., Teixeira, C.F.P., Fernández, C.M., Díaz, C., Gutiérrez, J.M., 2002. Increments in cytokines and matrix metalloproteinases in skeletal muscle after injection of tissue-damaging toxins from the venom of the snake *Bothrops asper*. *Mediators Inflamm.* 11, 121–128.
- Sami, R.P., Gopalakrishnakone, P., Ho, B., Chow, V.T.K., 2008. Purification, characterization and bactericidal activities of basic phospholipase A₂ from the venom of *Agkistrodon halys* (Chinese pallas). *Biochimie* 90, 1–17.
- Sanchez, E.F., Gabriel, L.M., Gontijo, S., Gremiski, L.H., Veiga, S.S., Richardson, M., 2007. Isolation and properties of a P-III metalloproteinase, leucurolysin-β, from *Bothrops leucurus* venom. *Comp. Biochem. Physiol., Part A* 148, S105–S106.
- Santos-Filho, N.A., Silveira, L.B., Oliveira, C.Z., Bernardes, C.P., Menaldo, D.L., Fuly, A.L., Arantes, E.C., Sampaio, S.V., Mamede, C.C.N., Beletti, M.E., Oliveira, F., Soares, A.M., 2008. A new acidic myotoxic, anti-platelet and prostaglandin I₂ inducer phospholipase A₂ isolated from *Bothrops moojeni* snake venom. *Toxicon* 52, 908–917.
- Sawai, Y., 1980. Studies on snakebites in the Asian areas. In: Eaker, D., Wadström, T. (Eds.), *Natural Toxins*. Pergamon Press, Oxford, pp. 25–32.
- Schaloske, R.H., Dennis, E.A., 2006. The phospholipase A₂ superfamily and its group numbering system. *Biochim. Biophys. Acta* 1761, 1246–1259.
- Selistre, H.S., Queiroz, L.S., Cunha, O.A.B., de Souza, G.E.P., Giglio, J.R., 1990. Isolation and characterization of hemorrhagic, myonecrotic and edema-inducing toxins from *Bothrops insularis* (jararaca ilhoa) snake venom. *Toxicon* 28, 261–273.
- Soares, A.M., Guerra-Sá, R., Borja-Oliveira, C.R., Rodrigues, V.M., Rodrigues-Simioni, L., Rodrigues, V., Fontes, M.R.M., Lomonte, B., Gutiérrez, J.M., Giglio, J.R., 2000. Structural and functional characterization of BnSP-7, a Lys49 myotoxic phospholipase A₂ homologue from *Bothrops neuwiedi pauloensis* venom. *Arch. Biochem. Biophys.* 378, 201–209.
- Stábeli, R.G., Amui, S.F., Sant'ana, C.D., Pires, M.G., Nomizo, A., Monteiro, M.C., Romão, P.R.T., Guerra-Sá, R., Vieira, C.A., Giglio, J.R., Fontes, M.R.M., Soares, A.M., 2006. *Bothrops moojeni* myotoxin-II, a Lys49-phospholipase A₂ homologue: an example of function versatility of snake venom proteins. *Comp. Biochem. Physiol. C* 142, 371–381.
- Teixeira, C.F.P., Landucci, E.C.T., Antunes, E., Chacur, M., Cury, Y., 2003. Inflammatory effects of snake venom myotoxic phospholipases A₂. *Toxicon* 42, 947–962.
- Teixeira, C.F.C., Cury, Y., Moreira, V., Picolo, G., Chaves, F., 2009. Inflammation induced by *Bothrops asper* venom. *Toxicon* 54, 67–76.
- Torres, A.F.C., Dantas, R.T., Menezes, R.R.P.P.B., Toyama, M.H., Filho, E.D., Oliveira, M.F., Nogueira, N.A.P., Oliveira, M.R., Monteiro, H.S.A., Martins, A.M.C., 2010. Antimicrobial activity of an L-amino acid oxidase isolated from *Bothrops leucurus* snake venom. *J. Venomous Anim. Toxins Incl. Trop. Dis.* 16, 614–622.
- Tsai, I.H., Wang, Y.M., Chen, Y.H., Tsai, T.S., Tu, M.C., 2004. Venom phospholipases A₂ of bamboo viper (*Trimeresurus stejnegeri*): molecular characterization, geographic variations and evidence of multiple ancestries. *Biochem. J.* 377, 215–223.
- van Deenen, L.L.M., de Haas, G.H., 1963. The substrate specificity of phospholipase A₂. *Biochem. Biophys. Acta* 70, 538–553.
- Ward, R.J., Oliveira, A.H., Bortoleto, R.K., Rosa, J.C., Faca, V.M., Greene, L.J., 2001. Refolding and purification of Bothropstoxin-I, a Lys-49 phospholipase A₂ homologue, expressed as inclusion bodies in *Escherichia coli*. *Protein Expr. Purif.* 21, 134–140.
- Wei, J.F., Wei, X.L., Chen, Q.Y., Huang, T., Qiao, L.Y., Wang, W.Y., Xiong, Y.L., He, S.H., 2006a. N49 phospholipase A₂, a unique subgroup of snake venom group II phospholipase A₂. *Biochim. Biophys. Acta* 1760, 462–471.
- Wei, J.F., Li, T., Wei, X.L., Sun, Q.Y., Yang, F.M., Chen, Q.Y., Wang, W.Y., Xiong, Y.L., He, S.H., 2006b. Purification, characterization and cytokine release function of a novel Arg-49 phospholipase A₂ from the venom of *Protobothrops mucrosquamatus*. *Biochimie* 88, 1331–1342.
- Zamuner, S.R., Zuliani, J.P., Fernandes, C.M., Gutiérrez, J.M., Teixeira, C.F.P., 2005. Inflammation induced by *Bothrops asper* venom: release of proinflammatory cytokines and eicosanoids, and role of adhesion molecules in leukocyte infiltration. *Toxicon* 46, 806–813.
- Zuliani, J.P., Fernandes, C.M., Zamuner, S.R., Gutiérrez, J.M., Teixeira, C.F.P., 2005. Inflammatory events induced by Lys-49 and Asp-49 phospholipases A₂ isolated from *Bothrops asper* venom: role of catalytic activity. *Toxicon* 45, 335–346.